Switch theme
Sign up to access all valuation multiples
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
5
Last FY Revenue $3.8M
Last FY EBITDA -$1.3M
$5.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Newbury Pharmaceuticals achieved revenue of $3.8M and an EBITDA of -$1.3M.
Newbury Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Newbury Pharmaceuticals valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.8M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 44% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -33% | XXX | XXX | XXX |
| EBIT | XXX | -$1.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -39% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.6M | XXX | XXX | XXX |
| Net Margin | XXX | -42% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Newbury Pharmaceuticals's stock price is SEK 3 (or $0).
Newbury Pharmaceuticals has current market cap of SEK 63.8M (or $6.6M), and EV of SEK 50.9M (or $5.3M).
See Newbury Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.3M | $6.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Newbury Pharmaceuticals has market cap of $6.6M and EV of $5.3M.
Newbury Pharmaceuticals's trades at 2.7x EV/Revenue multiple, and -3.2x EV/EBITDA.
Equity research analysts estimate Newbury Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Newbury Pharmaceuticals's P/E ratio is not available.
See valuation multiples for Newbury Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.6M | XXX | $6.6M | XXX | XXX | XXX |
| EV (current) | $5.3M | XXX | $5.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNewbury Pharmaceuticals's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.6M for the same period.
Newbury Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Newbury Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Newbury Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Newbury Pharmaceuticals acquired XXX companies to date.
Last acquisition by Newbury Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Newbury Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Newbury Pharmaceuticals headquartered? | Newbury Pharmaceuticals is headquartered in Sweden. |
| How many employees does Newbury Pharmaceuticals have? | As of today, Newbury Pharmaceuticals has 5 employees. |
| Is Newbury Pharmaceuticals publicy listed? | Yes, Newbury Pharmaceuticals is a public company listed on STO. |
| What is the stock symbol of Newbury Pharmaceuticals? | Newbury Pharmaceuticals trades under NEWBRY ticker. |
| When did Newbury Pharmaceuticals go public? | Newbury Pharmaceuticals went public in 2022. |
| Who are competitors of Newbury Pharmaceuticals? | Similar companies to Newbury Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Newbury Pharmaceuticals? | Newbury Pharmaceuticals's current market cap is $6.6M |
| Is Newbury Pharmaceuticals profitable? | Yes, Newbury Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
